Despite improvements in outcomes with tyrosine‐kinase inhibitors (TKIs) for patients with ABL‐class Ph‐like ALL,4 the overall prognosis for Ph‐like ALL remains inferior, with a 5‐year event‐free survival (EFS) rate of 22.5% and an overall survival (OS) rate of 23.8%, compared to 50%–60% OS observed in other subsets of Ph‐negative (Ph−) ALL.3 The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.